Dynavax Technologies Corporation

Equities

DVAX

US2681582019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
11.39 ^USD	+2.52%		+3.26%	-18.53%

May. 14	Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data	MT
May. 14	Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA	DJ

Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024

May 08, 2024 at 04:01 pm EDT

Dynavax Technologies Corporation reaffirmed financial guidance for the full year 2024. For the year, the company expects HEPLISAV-B net product revenue between approximately $265 million - $280 million, including approximately $3 million in ex-U.S. sales through commercialization partnership in Germany.

Latest news about Dynavax Technologies Corporation

Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data	May. 14	MT
Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA	May. 14	DJ
US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine	May. 14	RE
Dynavax Technologies Corporation Provides Regulatory Update on sBLA for Four-Dose HEPLISAV-B® Regimen for Adults on Hemodialysis in the U.S	May. 14	CI
Transcript : Dynavax Technologies Corporation, Q1 2024 Earnings Call, May 08, 2024	May. 08
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Posts Q1 Revenue $50.8M, vs. Street Est of $55M	May. 08	MT
Dynavax Technologies Corporation Reaffirms Financial Guidance for the Full Year 2024	May. 08	CI
Dynavax Technologies Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Dynavax Technologies Corporation Announces Chief Financial Officer Changes	Apr. 01	CI
Dynavax Technologies Reports Breakeven Q4 Earnings, Lower Revenue	Feb. 23	MT
Transcript : Dynavax Technologies Corporation, Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Dynavax Technologies Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q4 Revenue $55.6M, vs. Street Est of $52.7M	Feb. 22	MT
Dynavax Technologies Corporation Provides Revenue Guidance for the Year 2024	Feb. 22	CI
Dynavax Technologies Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Goldman Sachs Initiates Dynavax Technologies at Neutral Rating With $20 Price Target	Feb. 01	MT
Transcript : Dynavax Technologies Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 11:15 AM	Jan. 11
Dynavax Technologies Corporation(NasdaqGS:DVAX) added to NASDAQ Biotechnology Index	Dec. 18	CI
Dynavax Technologies Insider Sold Shares Worth $300,000, According to a Recent SEC Filing	Nov. 07	MT
Dynavax Technologies Insider Sold Shares Worth $282,400, According to a Recent SEC Filing	Nov. 03	MT
Transcript : Dynavax Technologies Corporation, Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (DVAX) DYNAVAX TECHNOLOGIES Reports Q3 Revenue $69.5M, vs. Street Est of $61.4M	Nov. 02	MT
Dynavax Technologies Corporation Revises Earnings Guidance for the Full Year 2023	Nov. 02	CI
Dynavax Technologies Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Insider Sell: Dynavax Technologies	23-09-05	MT

Chart Dynavax Technologies Corporation

Duration

Period

More charts

Company Profile

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Dynavax Technologies Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.11 USD

Average target price

25.4 USD

Spread / Average Target

+128.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
DYNAVAX TECHNOLOGIES CORPORATION	-18.53%	1.45B
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs